ECM
NBIX icon

Everence Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Everence Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$397K Buy
3,011
+211
+8% +$28K 0.02% 450
2025
Q4 		$397K Hold
2,800
– – 0.02% 471
2025
Q3 		$393K Hold
2,800
– – 0.02% 481
2025
Q2 		$352K Sell
2,800
-690
-20% -$79.1K 0.02% 509
2025
Q1 		$386K Hold
3,490
– – 0.03% 449
2024
Q4 		$476K Buy
+3,490
New +$432K 0.03% 378

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Everence Capital Management's NBIX Position: Q1 2026 in Review

Everence Capital Management increased its Neurocrine Biosciences (NBIX) stake by 7.5% in Q1 2026, buying an estimated $28K and bringing the position to 3,011 shares worth $397K. The position accounts for 0.02% of the portfolio, ranked #450.

Everence Capital Management first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $476K in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Everence Capital Management held 3,011 shares of Neurocrine Biosciences worth $397K as of Q1 2026.
  • Everence Capital Management bought 211 Neurocrine Biosciences shares in Q1 2026, an estimated $28K.
  • Neurocrine Biosciences made up 0.02% of Everence Capital Management's portfolio in Q1 2026, its #450 holding.
  • Everence Capital Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Everence Capital Management's Neurocrine Biosciences position peaked at $476K in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.